COMPANY PROFILE


image

Summary


Quotient Sciences is a drug development and manufacturing accelerator supporting customers across the entire development pathway from candidate selection to commercial launch. We deliver uniquely integrated programs and a range of tailored services that dramatically shorten drug development times. We’re driven by an unswerving belief that ideas need to become solutions, and molecules need to become cures, fast. Because humanity needs solutions, fast.

Strategic Quote


“In 2008 we launched Translational Pharmaceutics™, an innovative platform which integrates drug product manufacturing and clinical testing activities, saving customers more than 12 months of time in their drug development plans. We have demonstrated the timeline acceleration translates into multi-million financial benefits for customers and also gives them a far greater chance of success in getting new medicines to patients, faster.”

-Mark Egerton, CEO, Quotient Sciences

Key Leadership


Mark Egerton, Chief Executive Officer

Mark joined Quotient as Chief Executive Officer in 2005 and has over 25 years’ experience in the pharmaceutical and biotech industry. He has worked in a range of organizations including large multinational pharmaceutical companies through to private venture funded biotechnology companies.

Following his PhD (Biochemistry, University of Edinburgh) and post-doctoral research (Biochemistry, Biozentrum, Basel), Mark began his pharmaceutical R&D career at Novartis (then Sandoz) in Switzerland and then AstraZeneca in the U.K. During this time he was responsible for discovery projects across a number of therapeutic areas. Mark then joined Incyte Pharmaceuticals, a Californian biotechnology company, where he was responsible for a business unit focused on the application of genomic technologies to pre-clinical development. He returned to the U.K. with Incyte Pharmaceuticals to head up European Business Operations and was responsible for leading that organisation to record levels of performance. Prior to joining Quotient, Mark was the Chief Business Officer at Oxagen, a U.K. biotech company focused on novel therapeutics for Respiratory diseases.

Gordon Cameron OBE, Chief Financial Officer

Gordon joined Quotient in 2007 as CFO and is responsible for all financial matters, including financial reporting, liaising with Quotient’s investors and lenders and leading fund-raisings and M&A activities. Gordon has over 25 years’ experience in the pharmaceutical and biotech industry, in both private equity-backed and public companies. He spent 11 years as CFO and then CEO of Acambis plc, a FTSE-350 vaccines development company. He headed up Acambis’ U.S. operations for five years, delivering a smallpox vaccine counter-bioterrorism contract for the U.S. Government. Prior to that, Gordon spent six years as an investment banker, primarily with N M Rothschild, where he advised clients on a variety of corporate finance transactions. He qualified as a Chartered Accountant with Ernst & Young. In 2004, Gordon was awarded the Officer of the Order of the British Empire for services to the British biotechnology industry in the U.S.

Primary Services


• Formulation Development • Clinical Trial Manufacturing • Commercial Manufacturing • Clinical Pharmacology • Drug Substance • Bioanalysis • Data Sciences • Drug Development Consulting

Additional Resources


Contact

Phone: U.K. +44 (0)115 974 9000 / U.S. +1 800 769 3518